[en] [en] OBJECTIVES: Intravenous thrombolysis (IVT) failure in acute ischemic stroke (AIS) is frequent, but its causes remain elusive. We investigated whether biologically relevant intrathrombus concentrations of tissue plasminogen activator (tPA) were achieved in failed IVT and whether neutrophil extracellular traps (NETs) contributed to this therapeutic failure.
METHODS: In this monocenter cohort study, 205 thrombi from AIS patients were analyzed. A total of 83 of these thrombi were compared for tPA content and 53 for their susceptibility to ex vivo thrombolysis according to IVT status. An additional subset of 69 AIS thrombi was used to decipher if and how NETs interfere with intrathrombus fibrinolysis.
RESULTS: Thrombi from IVT patients contained twice as much tPA than those from no-IVT patients (p < 0.0001). Plasminogen and tPA in AIS thrombi were associated with fibrin, leukocytes, and NETs. Although ex vivo addition of plasminogen did not cause lysis of either no-IVT or IVT thrombi, combining plasminogen with deoxyribonuclease 1 (DNase 1) helped translate the increased tPA content of IVT thrombi into increased thrombolysis. We further show that DNase 1 enables tPA- and plasmin-mediated thrombolysis by eliminating fibrinolysis inhibitors from AIS thrombi.
INTERPRETATION: These results indicate that intrathrombus tPA concentrations reached in failed IVT bear a therapeutic potential that is impaired by NETs, which favor intrathrombus retention of fibrinolysis inhibitors and may limit the availability of tPA and plasminogen for fibrinolysis. Our results stress the interest of DNase 1 to enhance the efficacy of current IVT tPA regimens. ANN NEUROL 2026.
Disciplines :
Neurology
Author, co-author :
Solo Nomenjanahary, Mialitiana; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France ; Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
Desilles, Jean-Philippe; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France ; Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France ; StrokeLink F-CRIN Research Network, Lille, France
Zemali, Fatima; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Perrot, Astride; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Di Meglio, Lucas; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France ; FHU NeuroVasc2030, Paris, France
Zalghout, Sara; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Fasille, Jéromine; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Neel, Jérémy; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Loyau, Stéphane; Université Paris Cité, Inserm, UMRS-1148, Laboratory for Vascular Translational Science, Paris, France
Labreuche, Julien; Department of Biostatistics, CHU Lille, Lille, France
Bourrienne, Marie-Charlotte; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France ; Laboratoire d'Hématologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
Faille, Dorothée ; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France ; Laboratoire d'Hématologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
Delvoye, François ; Université de Liège - ULiège > Département des sciences cliniques ; Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
Ollivier, Véronique; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Dupont, Sébastien; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Rogozarski, Jasmina; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France
Brikci-Nigassa, Nahida; Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
Medcalf, Robert L; Monash University Department of Medicine, Australian Center for Blood Diseases, Monash University, Clayton, Australia
Ajzenberg, Nadine; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France ; Laboratoire d'Hématologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France
Mazighi, Mikael; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France ; Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France ; StrokeLink F-CRIN Research Network, Lille, France ; FHU NeuroVasc2030, Paris, France ; Department of Neurology, GHU APHP NORD, Hôpital Lariboisière, Paris, France ; Institut Universitaire de France, Paris, France
Ho-Tin-Noé, Benoît ; Université Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France